p53, p63 and p73 in the wonderland of  S. cerevisiae

Olivier Billant; Marc Blondel; Cécile Voisset

doi:10.18632/oncotarget.18506

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

p53, p63 and p73 in the wonderland of S. cerevisiae

Olivier Billant, Marc Blondel and Cécile Voisset _

PDF | HTML | How to cite

Oncotarget. 2017; 8:57855-57869. https://doi.org/10.18632/oncotarget.18506

Metrics: PDF 2266 views | HTML 3229 views | ?

Abstract

Olivier Billant1, Marc Blondel1,* and Cécile Voisset1,*

1Inserm UMR 1078, Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé, Etablissement Français du Sang (EFS) Bretagne, CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire, Brest, France

*These authors have contributed equally to this work

Correspondence to:

Cécile Voisset, email: [email protected]

Marc Blondel, email: [email protected]

Keywords: p53, p63, p73, yeast, FASAY

Received: March 31, 2017 Accepted: April 26, 2017 Published: June 16, 2017

ABSTRACT

Since its discovery in 1979, p53 has been on the forefront of cancer research. It is considered a master gene of cancer suppression and is found mutated in around 50% of all human tumors. In addition, the progressive identification of p53-related transcription factors p63 and p73 as well as their multiple isoforms have added further layers of complexity to an already dense network. Among the numerous models used to unravel the p53 family mysteries, S. cerevisiae has been particularly useful. This seemingly naive model allows the expression of a functional human p53 and thus the assessment of p53 intrinsic transcriptional activity. The aim of this article is to review the various contributions that the budding yeast has made to the understanding of p53, p63 and p73 biology and to envision new possible directions for yeast-based assays in the field of cancer as well as other p53-family-related diseases.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18506

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

p53, p63 and p73 in the wonderland of S. cerevisiae

Abstract